Oral drugs and radiation for advanced colorectal cancer after standard therapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that is MSS (a type that doesn't typically respond well to immunotherapy alone) or pMMR.
- You are 18 years or older.
- You are able to take pills by mouth.
- You have had at least two prior standard treatments (including oxaliplatin, irinotecan, and fluorouracil) and your cancer has gotten worse.
- You have no more than 2 organs with cancer spread, the largest tumor is 5 cm or smaller, and you have 10 or fewer tumors total.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination of three drugs — an immunotherapy (sintilimab), a blood vessel growth blocker (bevacizumab), and a chemotherapy helper (decitabine) — for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer when standard options have failed.
This trial tests a combination of short-course radiation, chemotherapy, targeted therapy (bevacizumab), and an immunotherapy drug (PD-1 inhibitor) for people with advanced colorectal cancer that has spread and is not curable with surgery. It aims to see if this approach can help shrink tumors and improve outcomes.
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
This study tests a combination of precisely targeted radiation (SBRT) with two drugs: fruquintinib (a pill that blocks blood supply to tumors) and antibodies that boost your immune system to fight cancer (PD-1 and CTLA-4 inhibitors). It is for people with advanced colorectal cancer who have already tried two standard chemotherapy treatments.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This trial tests a new combination of high and low-dose radiation with immunotherapy and a targeted drug for advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this approach can help shrink tumors and improve outcomes.
Hear when a new Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.